CURE Pharmaceutical & Canopy Growth to Produce CBD Oral Thin Films

CURE Pharmaceutical recently announced it is collaborating with Canopy Growth Corporation to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm technology for global distribution. This CUREfilm license gives Canopy a dosage form that is ideal for administering cannabinoids.

“This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. “We will leverage our recent patented developments in cannabis-based drug delivery, to formulate an oral thin film product for optimal efficacy and dosing frequency.”

CURE is registered with the US Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, CA. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing, and greater palatability.

CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the US, Canada, and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced. For more information, visit www.curepharma.com.

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. Canopy Growth has operations in 10 countries across five continents. The company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its fully owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, Canopy Growth is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information, visit www.canopygrowth.com.